Final Program

Cellular Therapy 2015
March 19 and 20, 2015, Erlangen, Germany
8th International Symposium on the Clinical Use of Cellular Products

Cellular Therapy 2015

March 19 and 20, 2015

Department of Internal Medicine 5 – Hematology/Oncology
University of Erlangen-Nuremberg

Department of Dermatology
University of Erlangen-Nuremberg

Department of Internal Medicine 3 – Hematology/Oncology
University of Regensburg

Unter der Schirmherrschaft der

DGHO
DEUTSCHE GESELLSCHAFT FÜR HÄMATOLOGIE UND MEDIZINISCHE ONKOLOGIE
Cooperating Institutions

i-Target, Elitenetzwerk Bayern

BayImmuNet Bavarian Immunotherapy Network

SFB 643 Strategies of Cellular Immune Intervention

GK1660 Adaptive Immunity

MICE Medical Immunology Campus Erlangen

Comprehensive Cancer Center Erlangen
Europäische Metropolregion Nürnberg
Welcome Address

Dear Colleagues.

On behalf of the organizing committee we would like to invite you to join us for the 8th International Cellular Therapy Symposium, to be held in Erlangen, Germany, from March 19 to 20, 2015. The Cellular Therapy Symposium will be co-organized by the Universities of Erlangen-Nuremberg (A. Mackensen; G. Schuler) and Regensburg (W. Herr).

Over the past years the meeting has evolved to a widely respected event, attracting experts from all over the world to discuss recent topics of the field in a pleasant environment. The upcoming meeting 2015 will focus on immune effector cells, B cells, suppressor cells, CAR/TCR-engineered T-cell therapy, immunological checkpoints, antigen processing & presentation and systems biology.

We are sure that your participation will contribute making the meeting exciting and successful. You are cordially invited to join us at this symposium in the beautiful city of Erlangen.

Yours sincerely

Prof. Andreas Mackensen
General Information

Organizer:
Prof. Dr. A. Mackensen
Department of Internal Medicine 5 – Hematology and Oncology
Ulmenweg 18
D-91054 Erlangen, Germany
Phone: +49-9131-85 35954
Fax: +49-9131-85 35958
E-mail: andreas.mackensen@uk-erlangen.de
liane.bischoff-ziebell@uk-erlangen.de

Conference Site
Hörsaalgebäude
Universitätsklinikum Erlangen
Ulmenweg 18
91054 Erlangen
Germany

Coffee Break and Lunch
During session breaks, coffee and cake will be served to participants wearing their badges. The coffee break will take place in the lobby.
Lunch on March 19 and brunch on March 20 is included in the registration fee and will also take place in the lobby.

Social Event
A social evening with dinner and live music will be organized at the restaurant Schloss Atzelsberg, Marloffstein-Atzelsberg, on Thursday, March 19 at 18.30 h (6.30 pm).
General Information

Opening Hours of the Conference Office
Wednesday, March 18, 2015  15.00 – 17.00 h
Thursday, March 19, 2015  08.00 – 18.00 h
Friday, March 20, 2015   08.30 – 16.00 h

During the conference you can contact us by phone or fax
Phone: +49-91 31-85 43100
Fax: +49-91 31-85 35758
Mobile phone: +49-173-8611442

Registration:
Participants can register onsite (cash only)
Full Registration: 300 €
Students: 175 €
Employees of the Universities Erlangen & Regensburg: 50 €
The registration fee covers conference volume, coffee breaks, lunch, brunch and social event.

Tourist Information Erlangen
Erlanger Tourismus und Marketing Verein e.V.
Carree am Rathausplatz
Rathausplatz 3
91052 Erlangen
Phone: +49 (0)91 31 89 51-11
Fax: +49 (0)91 31 89 51-51
Mail: katja.rueth@etm-er.de
Organizer:
Andreas Mackensen, Erlangen
Gerold Schuler, Erlangen
Wolfgang Herr, Regensburg

Scientific Committee:
Andreas Mackensen, Erlangen
Wolfgang Herr, Regensburg
Armin Gerbitz, Erlangen
Gerold Schuler, Erlangen
Anita Kremer, Erlangen
Dimitrios Mougiakakos, Erlangen
Diana Dudziak, Erlangen
Alexander Steinkasserer, Erlangen
Thomas Winkler, Erlangen
Matthias Theobald, Mainz
Petra Hoffmann, Regensburg
Matthias Edinger, Regensburg
Joachim Schultze, Bonn
Wolfgang Uckert, Berlin
Robert Zeiser, Freiburg

Congress Secretary:
Armin Gerbitz
Department of Internal Medicine 5 – Hematology and Oncology
Ulmenweg 18
D-91054 Erlangen, Germany
Phone: +49-9131-85 35954
Fax: +49-9131-85 35958
Mail: info@cellular-therapy.de
Thursday March 19, 2015

09.00 h

Opening

Andreas Mackensen
Director of the Department of Internal Medicine 5 – Hematology and Oncology
University of Erlangen-Nuremberg
Thursday March 19, 2015

Session I

Immune Effector Cells

9.15 h - 11.00 h

Chairmen: Wolfgang Herr (Regensburg)
           Hermann Einsele (Würzburg)
Thursday March 19, 2015

Session I

01 09.15–09.40  Role of mTOR signalling in steering T-cell differentiation during adaptive immune responses  
                P. Romero, Lausanne

02 09.40–09.50  Expansion of human CD4+ T cells in vitro by bead-bound conventional anti-CD28 monoclonal antibodies  
                N. Beyersdorf, Würzburg

03 09.50–10.15  In vivo discovery of targets for cancer immunotherapy  
                K. Wucherpfennig, Boston

04 10.15–10.25  RNA-sequence analysis as novel method for identification of hematopoiesis restricted minor histocompatibility antigen LB-ITGB2-1  
                M. Pont, Leiden

05 10.25–10.50  NK cells in the immunotherapy of leukemia  
                K. Rezvani, Houston

06 10.50–11.00  Evaluating human T-cell therapy of cytomegalovirus organ disease in HLA-transgenic mice  
                S. Thomas, Regensburg

11.00-13.30  Lunch and Poster Discussion
Authors are requested to be present at their poster
Thursday March 19, 2015

Session II

CAR/TCR-engineered T-Cell Therapy

13.30 h - 15.15 h

Chairmen: Wolfgang Uckert (Berlin)
Claudia Rössig (Münster)
Thursday March 19, 2015

Session II

07 13.30-13.55  CAR T-cell therapy: the CD19 paradigm
        M. Sadelain, New York

08 13.55-14.05  Analyzing therapeutic efficacy of melanoma-specific
        TCR gene therapy in a HLA-A2-transgenic syngeneic cancer model
        M. Leisegang, Berlin

09 14.05-14.30  Enhancing the synthetic IQ of CAR T Cells
        M. Jensen, Seattle

10 14.30-14.40  T-cell lineage specification of Chimeric Antigen Receptor
        (CAR)-targeted induced pluripotent stem (iPS) Cells
        M. Themeli, New York

11 14.40-15.05  WT1 TCR gene therapy for leukemia
        E. Morris, London

12 15.05-15.15  Antigen-specific TCR-modified Treg for treatment of EAE
        E. Kieback, Berlin

15.15-15.45  Coffee Break
Thursday March 19, 2015

Session III

B-Lymphocytes

15.45 h - 17.30 h

Chairmen: Lars Nitschke (Erlangen)
Petra Hoffmann (Regensburg)
Thursday March 19, 2015

Session III

13  15.45-16.10  B10 cells – a functionally defined regulatory B-cell subset
              T. Tedder, Durham

14  16.10-16.20  GVHD after allogeneic BMT blocks early B cell
              differentiation
              K. Doser, Regensburg

15  16.20-16.45  Adoptive B-cell therapy after allogeneic stem cell
              transplantation
              T. Winkler, Erlangen

16  16.45-16.55  B cell inhibition by crosslinkage of CD79b is superior
              over B cell depletion with antibodies against CD20 in murine collagen-induced arthritis and completely stops
              ongoing humoral immune responses
              M. Mack, Regensburg

17  16.55-17.20  Antibody-independent functions of plasma cells:
              a view from the cytokine world
              S. Fillatreau, Berlin

18  17.20-17.30  In vitro and in vivo imaging of the migratory behavior of
              CD40-activated B cells in the setting of cancer
              immunotherapy
              K. Wennhold, Cologne

18.30  Social Event:
       Schloss Atzelsberg, Marloffstein-Atzelsberg
Friday March 20, 2015

Session IV

Immunological Checkpoints

09.15 h – 11.00 h

Chairmen: Matthias Theobald (Mainz)
           Alexander Steinkasserer (Erlangen)
Friday March 20, 2015

Session IV

19 09.15-09.40  T-cell metabolism and antitumor immunity
L. Gattinoni, Washington

20 09.40-09.50  Metabolic restriction preserves human CD4 and CD8 T cell effector function
K. Renner, Regensburg

21 09.50-10.15  Immune targeting of regulatory mechanisms
M. H. Andersen, Herlev

22 10.15-10.25  A new fusion receptor overcomes PD-1-mediated immunosuppression in adoptive T cell therapy
S. Kobold, München

23 10.25-10.50  Immunological biomarkers for studying checkpoint inhibitors in the clinic
John Haanen, Amsterdam

11.00-12.00  Brunch
Friday March 20, 2015

Session V

Antigen Processing & Presentation

12.00 h - 13.45 h

Chairmen: Anita Kremer (Erlangen)
Matthias Edinger (Regensburg)
<table>
<thead>
<tr>
<th>No.</th>
<th>Time</th>
<th>Title</th>
<th>Speaker, Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
<td>12.00-12.25</td>
<td>Dendritic cell biology in the context of immunotherapy for infection and cancer</td>
<td>C. Reis e Sousa, London</td>
</tr>
<tr>
<td>26</td>
<td>12.35-13.00</td>
<td>Dendritic cell targeting facilitating cross presentation</td>
<td>Y. van Kooyk, Amsterdam</td>
</tr>
<tr>
<td>27</td>
<td>13.00-13.10</td>
<td>Indirect presentation of Y-chromosome antigen DBY requires protein structures outside of the T-cell epitope</td>
<td>S. Kretschmann, Erlangen</td>
</tr>
<tr>
<td>28</td>
<td>13.10-13.35</td>
<td>Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing</td>
<td>I. Mellman, San Francisco</td>
</tr>
<tr>
<td>29</td>
<td>13.35-13.45</td>
<td>Tumor cell recognition of g9d2TCR T cells is dictated via Small Rho GTPase by linking mevalonate pathway to BTN3A1 (CD277)</td>
<td>Z. Sebestyen, Utrecht</td>
</tr>
<tr>
<td></td>
<td>13.45-14.15</td>
<td>Coffee Break</td>
<td></td>
</tr>
</tbody>
</table>
Friday March 20, 2015

Session VI

Systems Biology in Cellular Therapy

14.15 h - 16.00 h

Chairmen: Robert Zeiser (Freiburg)  
            Diana Dudziak (Erlangen)
Friday March 20, 2015

Session VI

30 14.15-14.40  Systems immunology of vaccination
     A. K. Palucka, Houston

31 14.40-15.05  Molecular Control of Immune Cell Trafficking
     M. Sixt, Vienna

32 15.05-15.15  Analysis of Dendritic Cells in human lymphoid organs
     G. Heidkamp, Erlangen

33 15.15-15.25  Phenotypic signatures of immune sensitivity and resistance
     in melanoma micro-metastases elucidated using mathematical modeling
     J. V. Gonzáles, Erlangen

34 15.25-15.50  Transcriptome-based network analysis reveals a spectrum model of human macrophage activation
     J. Schultze, Bonn

15.50  Summary
     A. Mackensen
Thursday March 19, 2015

Poster Session

11.00 h - 13.30 h
Poster Session A

Immune Effector cells
(T cells, NK cells)

A1  5-deoxy-5-methylthioadenosine suppresses human T-cell functions by influencing AKT signalling
    M. Aigner, Erlangen

A2  A novel soluble and reversible cell activation system
    P. Gräf, Göttingen

A3  Analysis of autologous, dendritic cell-stimulated CD8+ T-cells by a novel real time killing assay
    K. Friedmann, Homburg

A4  CD4 T cells recognizing tissue specific antigens in mismatched HLA-DP can mediate graft versus host disease.
    L. Meintker, Leiden

A5  Characterization of Human Natural Killer Cell Activity against Multiple Myeloma
    S. Tognarelli, Frankfurt

A6  Co-stimulatory and co-inhibitory cell surface signaling molecules are involved in target-induced inhibition of T-cell responses against acutelymphoblastic leukemia
    J. Feucht, Tübingen

A7  Compound A reduced the proliferation of T cells but induced a higher cell infiltration in the target organ
    A. Bouazzaoui, Regensburg

A8  Differences in NK cell reconstitution after T cell depletion with ATG or Alemtuzumab in allogeneic hematopoetic stem cell transplantation
    S. Bode, Mainz

A9  Effect of re-cultivation and interleukin 2 presence on cytotoxic potential of cryopreserved NK cells
    M. Holubova, Pilsen
<table>
<thead>
<tr>
<th>A10</th>
<th>Exploring the association of immune cell infiltration and lymphangiogenesis in ocular melanoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M. Karg, Erlangen</td>
</tr>
<tr>
<td>A11</td>
<td>Functionally impaired GPI-anchor negative regulatory T cells strongly correlate with acute Graft versus Host Disease after Alemtuzumab-based conditioning regimen</td>
</tr>
<tr>
<td></td>
<td>K. Epp, Mainz</td>
</tr>
<tr>
<td>A12</td>
<td>High prevalence of functional la specific cytotoxic T lymphocytes in healthy individuals – implications for strategies in adoptive T cell therapies of relapsed leukemia</td>
</tr>
<tr>
<td></td>
<td>S. Matko, Dresden</td>
</tr>
<tr>
<td>A13</td>
<td>IL-17A mediates anti-viral properties in allergic asthma</td>
</tr>
<tr>
<td></td>
<td>A. Graser, Erlangen</td>
</tr>
<tr>
<td>A14</td>
<td>Impaired NK cell subset reconstitution correlates with development of acute GVHD following allogeneic stem cell transplantation</td>
</tr>
<tr>
<td></td>
<td>E. Ullrich, Frankfurt</td>
</tr>
<tr>
<td>A15</td>
<td>Impairment of T-bet-mediated Immune Responses in the Tumoural Region of Lung Adenocarcinoma</td>
</tr>
<tr>
<td></td>
<td>K. Andreev, Erlangen</td>
</tr>
<tr>
<td>A16</td>
<td>In vivo silencing of A20 via TLR9-mediated targeted siRNA delivery potentiates antitumor immune response</td>
</tr>
<tr>
<td></td>
<td>P. Grabarczyk, Greifswald</td>
</tr>
<tr>
<td>A17</td>
<td>Induction of anti tumor responses against malignant melanoma via antigen targeting in vivo</td>
</tr>
<tr>
<td></td>
<td>C. Lehmann, Erlangen</td>
</tr>
<tr>
<td>A18</td>
<td>Metabolic programming of human CD8+ T-cells in the context of T-cell priming</td>
</tr>
<tr>
<td></td>
<td>S. Hüper, Würzburg</td>
</tr>
<tr>
<td>A19</td>
<td>Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by zVAD-fmk has immunostimulant anti-tumor effects</td>
</tr>
<tr>
<td></td>
<td>N. Werthmüller, Erlangen</td>
</tr>
<tr>
<td>A20</td>
<td>Multicolour flow cytometry quantification of immune affinity selected CMV antigen specific T-cell in clinical scale preparations with two different devices</td>
</tr>
<tr>
<td></td>
<td>S. Klöß, Hannover</td>
</tr>
</tbody>
</table>
NFATc1 deletion in T lymphocytes inhibits the allergic trait in asthma
S. Koch, Erlangen

NK cell reconstitution after high-dose chemotherapy and autologous stem cell transplantation: subpopulations, phenotype and function
B. Jacobs, Oslo

Optimization of Cytokine Activation by Addition of IL-21 Enhances Antitumor Impact of Adoptive NK Cell Therapy Protocols against Rhabdomyosarcoma
J. Wagner, Frankfurt

Optimizing NK cell therapy through SMAC mimetics – a double hit strategy
K. Fischer, Frankfurt

Prophylactic application of escalating doses of donor-derived central memory T lymphocytes (Tcm) after allogeneic hematopoetic progenitor cell transplantation (HPCT) to prevent infectious complications (PACT)
K. Weiß, München

Selection of Adenovirus and Epstein-Barr-virus-specific T-cells with MHC class I streptamers under good manufacturing practice (GMP)-compliant conditions
C. Freimüller, Wien

Src kinase Lyn acts as a regulatory feed-back loop on TLR4-induced IL12-production in human dendritic cells
Y. Yoo, Würzburg

Stimulation of protein-reactive effector cells by activated proteins: a novel strategy for monitoring cell mediated immunity
K. Böckl, Regensburg

The Dual-Dual-Targeting (DDT) Concept - Activating NK Cell Receptors as Trigger Molecules for Bifunctional Antibody-Derivatives to Enhance Anti-Tumor NK cell Responses
M. Peipp, Kiel

The immune response of allergic asthma is modulated by the AP-1 transcription factor BATF
N. Sopel, Erlangen

Virus-activated plasmacytoid dendritic cells induce apoptosis and necrosis in melanoma cells
S. Thomann, Erlangen
Poster Session B

Suppressor cells (Treg, MDSC, MSC)

**B1** Induced regulatory T cells suppress B cells in an MHC-II and PD-1-dependent manner
*J. Gotot, Bonn*

**B2** Metabolic reprogramming of acute myeloid leukemia blasts by bone marrow stromal cells
*M. Braun, Erlangen*

**B3** Therapeutic effect of donor regulatory T cells in graft-versus-host disease
*C. Riegel, Regensburg*

**B4** GP120-activated regulatory T cells for prevention of Graft-versus-host disease after allogeneic stem cell transplantation
*M. Sommer, Mainz*
Poster Session C

CAR/TCR-Therapy

C1 A dual-targeting approach with CAR NK cells for adoptive immunotherapy of glioblastoma
S. Genssler, Frankfurt

C2 B-cell lineage specific T-cell adoptive transfer therapy: targeting CD79
S. Boiani, Berlin

C3 Customized CAR design for optimal anti-tumor function: length and composition of the extracellular spacer domain is a decisive feature for CAR-engineered T cells
M. Hudecek, Würzburg

C4 Generation of CD8+ T cells expressing two additional T-cell receptors (TETARs) for personalised melanoma therapy
S. Höfflin, Erlangen

C5 Generation of HLA*A02:01 restricted CD19 specific T-cells in CD19 non-tolerant hosts
A. Maurberger, Erlangen

C6 Human cytomegalovirus infection protects fibroblasts against lysis by T cells redirected by a CAR against glycoprotein B
J. Proff, Erlangen

C7 Human papillomavirus oncogene-specific TCR for immunotherapy
F. Lorenz, Berlin

C8 Inducible T-cell receptor expression in precursor T-cells for leukemia control
M. Sauer, Hannover

C9 Isolation of NY-ESO-1-specific T cell receptors restricted by non-HLA-A*02:01 allotypes for TCR gene therapy
S. Wilde, München

C10 Next generation of CAR T cells: TRUCKs and beyond
H. Abken, Köln
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Targeted NK cells for adoptive immunotherapy of glioblastoma</td>
<td>C. Zhang, Frankfurt</td>
</tr>
<tr>
<td>Transduction with C-C-chemokine receptor type 4 (CCR4) enhances tumor-specific migration of adoptively transferred T cells in a model of pancreatic cancer</td>
<td>M. Rapp, München</td>
</tr>
<tr>
<td>Untouched GMP-grade purified engineered immune cells</td>
<td>Z. Sebestyen, Utrecht</td>
</tr>
<tr>
<td>Genetically modified cytokine-induced killer (CIK) cells for targeted cancer therapy</td>
<td>S. Oelsner, Frankfurt</td>
</tr>
<tr>
<td>Generation of tumor-specific NK cells by differentiation of CAR-gene transduced hematopoietic stem cells</td>
<td>P. Oberoi, Frankfurt</td>
</tr>
</tbody>
</table>
Poster Session D

B cells

D1  Adoptive transfer of purified donor-B-lymphocytes after allogeneic stem cell transplantation: first results from a Phase I/IIa study  
*J. Winkler, Erlangen*

D2  IL-21 induces granzyme B-expressing regulatory B cells (GraB cells) in humans  
*B. Jahresdörfer, Ulm*

D3  Tumor-associated regulatory B cells in esophago-gastric cancer  
*H. Schlösser, Köln*
Poster Session E

Immunological Checkpoints

E1  Ewing Sarcoma shapes immune-inhibitory tumor microenvironment by local HLA-G expression
    C. Spurny, Münster

E2  Immune checkpoints PDL-1 and CTLA-4 in gastric cancer
    H. Schlösser, Köln

E3  Interleukin-7 represses the immunoregulatory function of human double-negative T cells by activating Akt/mTOR signaling
    A. Allgäuer, Erlangen

E4  Ionizing radiation is combinable with an autologous whole tumour cell based vaccine generated by high hydrostatic pressure technology
    B. Frey, Erlangen

E5  The oxidative burst mediates anti-inflammatory clearance of dead cells in a mouse model of Systemic Lupus Erythematosus and inflammatory Arthritis
    D. Kienhöfer, Erlangen
**Poster Session F**

**Antigen Processing & Presentation**

**F1** A new method to monitor antigen-specific CD8+ T-cells, avoiding additional target cells and the restriction human leukocyte antigen haplotype  
*S. Prommersberger, Erlangen*

**F2** Anti-inflammatory Effects of MCS-18 on Dendritic Cells and Endothelial cells - Impact on Advanced Atherosclerosis in ApoE-deficient Mice  
*C. Kühn, Erlangen*

**F3** Antigen targeting of Fc-receptors induces strong T cell responses in vivo  
*C. Lehmann, Erlangen*

**F4** Assessing response to Dendritic Cell Cancer Immunotherapy using immune-biomarkers  
*C. Visus, Wien*

**F5** Comparison of monocytapheresis products with two different programs  
*H. Pfeiffer, Erlangen*

**F6** DC subpopulation specific changes of the cross-presentation machinery under inflammatory conditions  
*D. Dudziak, Erlangen*

**F7** Erythrocytes used as carrier to target antigen-presenting cells enhance specific immune response  
*W. Berlier, Lyon*

**F8** Granzyme B is a key determinant of plasmacytoid dendritic cell immunogenicity  
*T. Trzska, Ulm*

**F9** Identification of HLA-C restricted, HIV-1-specific CTL epitopes by peptide induced upregulation of HLA-C expression  
*A. Stoll, Erlangen*
F10 Immunotherapy of Merkel Cell Carcinoma by DC vaccination against the viral oncogenic driver large T antigen
K. Gerer, Erlangen

F11 In vitro generation of tumor lysate-pulsed dendritic cells with immunotherapeutic potential
A. Pinho, Porto

F12 Indirect presentation of Y-chromosome antigen DBY requires protein structures outside of the T-cell epitope
S. Kretschmann, Erlangen

F13 Specialization of human myeloid Dendritic Cells Type 1 for extracellular pathogens
L. Heger, Erlangen
Poster Session G

Systems Biology in Cellular Therapy

G1  Analysis of homing and engraftment of hematopoietic stem cells after allogeneic stem cell transplantation  
C. Hart, Regensburg

G2  Effects of Human Bone Marrow Mesenchymal Stem Cells and Umbilical Cord Stem Cells on Diabetic Nephropathy in db/db mice  
J. Xie, München

G3  Fractionated radiotherapy and not chemotherapy with temozolomide or valproic acid is the main stimulus for the induction of immunogenic glioma cell death in primary glioma cells isolated from a patient with GBM  
Y. Rubner, Erlangen
Invited Speakers

Andersen, Mads Hald
Center for Cancer Immune Therapy (CCIT)
Department of Hematology
Copenhagen University Hospital,
DK-2730 Herlev
Denmark
Mads.Hald.Andersen@regionh.dk

Fillatreau, Simon
Deutsches Rheuma-Forschungszentrum (DRFZ) Berlin
Charitéplatz 1
10117 Berlin
Germany
fillatreau@drfz.de

Gattinoni, Luca
Experimental Transplantation and Immunology Branch,
Center for Cancer Research,
National Cancer Institute,
National Institutes of Health,
Bethesda, MD 20892,
USA
Luca_Gattinoni@nih.gov

Haanen, John
The Netherlands Cancer Institute
Plesmanlaan 121
1066 CX Amsterdam
The Netherlands
j.haanen@nki.nl

Jensen, Michael
Seattle Children’s Research Institute
OL-1 - Ben Towne Center for Childhood Cancer Research
1100 Olive Way
Seattle, WA 98101
USA
michael.jensen@seattlechildrens.org

van Kooyk, Yvette
Department of Molecular Cell Biology and Immunology
Vumc
FdG A224
van der Boechorststraat 7
1081BT Amsterdam
The Netherlands
y.vankooyk@vumc.nl

Mellman, Ira
Genentech
1 DNA Way,
San Francisco, California 94080
USA
mellman.ira@gene.com

Morris, Emma
Department of Immunology, UCL Medical School
Royal Free Campus, Royal Free Hospital
London
NW3 2PF
United Kingdom
e.morris@ucl.ac.uk

Palucka, Anna Karolina
Baylor Institute for Immunology Research,
Ralph M. Steinman Center for Cancer Vaccines,
Dallas, TX 75204,
USA
Karolina.Palucka@jax.org

Reis e Sousa, Caetano
London Research Institute
Cancer Research UK
Room 121, 44 Lincoln’s Inn Fields
London WC2A 3LY
United Kingdom
Caetano@cancer.org.uk
Invited Speakers

Rezvani, Katy
SCT Laboratory and GMP Laboratory
Department of Stem Cell Transplantation and Cellular Therapy
The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Blvd, Box 448
Houston, TX 77030-4009
USA
krezvani@mdanderson.org

Romero, Pedro
Ludwig Center for Cancer Research of the University of Lausanne
Ch. des Boveresses 155
1066 Epalinges
Switzerland
pedro.romero@unil.ch

Sadelain, Michel
Center for Cell Engineering
Memorial Sloan Kettering Cancer Center
1275 York Avenue
New York
USA
m-sadelain@ski.mskcc.org

Schultze, Joachim
University of Bonn
Life & Medical Science Institute (LIMES)
Genomik & Immunoregulation
Carl-Troll Str. 31
53115 Bonn
Germany
j.schultze@uni-bonn.de

Sixt, Michael
Institute of Science and Technology Austria (IST Austria)
Am Campus 1
A – 3400 Klosterneuburg
Austria
michael.sixt@ist.ac.at

Tedder, Thomas
Duke University, Department of Immunology
Jones Building, Room 353
207 Research Drive
Duke Box Number 3010
Durham, NC 27710
USA
thomas.tedder@duke.edu

Winkler, Thomas
University of Erlangen-Nuremberg
Lehrstuhl für Genetik
Nikolaus-Fiebiger-Zentrum für Molekulare Medizin
Glückstrasse 6
91054 Erlangen
thomas.winkler@fau.de

Wucherpfennig, Kai
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA, 02215
USA
kai_wucherpfennig@dfci.harvard.edu
Major Sponsors

AMGEN

Onkologie

Bristol-Myers Squibb

Roche
Sponsors / Exhibitors

Sponsoring this event for purposes of advertising

- Alexion Pharma Germany GmbH  2.100 €
- AMGEN GmbH
- Astellas Pharma GmbH  2.100 €
- Bayer Vital GmbH  2.100 €
- Becton Dickinson GmbH – BD Biosciences  2.100 €
- Bristol-Myers Squibb GmbH & Co. KGaA  20.000 €
- Celgene GmbH  2.100 €
- CellGenix GmbH  2.100 €
- Cell-Medica Ltd.  2.100 €
- Consarctic GmbH  2.100 €
- eBioscience  2.100 €
- Eusa Pharma GmbH  2.100 €
- Gilead  2.100 €
- Janssen-Cilag GmbH  2.100 €
- Lonza Cologne GmbH  2.100 €
- Lophius Biosciences GmbH  2.100 €
- Medac GmbH  2.100 €
- Miltenyi Biotec GmbH  2.100 €
- MSD Sharp & Dohme GmbH  5.000 €
- Neovii Biotech GmbH  2.100 €
- Novartis Pharma GmbH  5.000 €
- Peprotech GmbH  2.100 €
- Pfizer Pharma GmbH  2.100 €
- Roche Pharma AG
- Therakos (UK) Limited  2.100 €
Cytovir CMV reconstitutes CMV-specific T cells post allo-HSCT

Cytovir CMV is a T cell therapy with Streptamer™-matched specificity for the human Cytomegalovirus (CMV) and is available for therapeutic use in patients to treat and prevent CMV infections after allogeneic hematopoietic stem cell transplantations (allo-HSCT). The safety and efficacy of Cytovir CMV were studied in two randomized studies ASPECT (NCT01220895) and IMPACT (NCT01077908).

In ASPECT, patients who were baseline negative for CMV-specific T cells at the time of viral reactivation and received, Cytovir CMV with standard best available anti-viral drug therapy (SBAT) demonstrated reconstitution through an increase in mean bloodstream CMV-specific T cells compared to SBAT alone and a statistically significant increase in mean [range] values for maximum change from baseline within the first eight weeks (p=0.0184).

In IMPACT, Cytovir CMV again administered with SBAT resulted in fewer CMV reactivations (0.75 vs. 1.0/ patient), fewer patients experienced >1 treatment episode compared to SBAT alone (15% vs. 26%) and there was a trend toward reduced overall treatment time duration, although statistical significance has not been reached.

1 <10x10⁶ / L Streptamer-specific T cells, 2 when required, 3 Peggs et al. Blood 2014; 124(21):1109

This product is now commercially available
For more information please contact us on: orders@cellmedica.co.uk

Prescribing information
Company: Cell Medica Ltd
Product name: Cytovir™ CMV
Composition of the product: Cytovir CMV is a formulation of naturally occurring CMV-specific cytotoxic T lymphocytes that are directly selected from a CMV-seropositive donor containing up to 3 x 10⁶ CD3+ T-cells/ kg body weight as suspension for infusion with a final concentration of 2.25% Human Serum Albumin and 10% dimethyl-sulfoxide.
Therapeutic indication: Cytovir CMV can be used for the pre-emptive treatment of Cytomegalovirus (CMV) infections after allogeneic hematopoietic stem cell transplantations (allo-HSCT). Cytovir CMV may also be used for the prophylactic and therapeutic treatment of CMV infection in patients after allo-HSCT.
Contraindications: Hypersensitivity to the active substance(s) or to any of the excipients.
Side-effects: In the completed study, a total of 24 serious adverse events (SAEs) were reported by 12 (42.9%) patients, seven (41.2%) in the ACT group and five (45.5%) in the Control group. Four (14.3%) patients died during the study, two (11.8%) in the ACT group and two (18.2%) in the Control group. The most frequently reported SAEs were GvHD (n=6), and CMV infection (n=4). The SAE of GvHD was reported by three (17.6%) patients in the ACT group and three (27.3%) patients in the Control group. The SAE of CMV infection (requiring admission for treatment) was reported more frequently in the ACT group than in the Control group (17.6% versus 9.1%). Adverse events should be reported to the HTA and Cell Medica.
Warnings and precautions: Cytovir CMV is a patient-specific product and must not be administered to anyone other than the named patient. Careful consideration should be given to the patient’s risk of complications associated with GvHD prior to initiating therapy. Acute reactions related to DMSO are a known risk such that patients should be monitored and given supportive care where necessary.
Legal category: Prescription only. Prescription information last revised: Oct 2014
Price: € 30,000

www.cellmedica.co.uk
Notes
8th International Symposium
on the Clinical Use of Cellular Products

Final Program

Cellular Therapy 2015
March 19 and 20, 2015, Erlangen, Germany